Stocks Down Under Videos

Get a 3-month FREE TRIAL to CONCIERGE now!

Concierge gives you timely BUY and SELL alerts on ASX-listed stocks

Prescient Therapeutics (ASX:PTX) CEO interview

November 15, 2023

Prescient Therapeutics, PTX

Prescient Therapeutics

We talked to Prescient Therapeutics‘ CEO Steve Yatomi-Clarke about the company’s PTX-100 programme, where a new drug is being developed for the treatment of T Cell Lymphoma. The Phase 1b data looks amazing, with a 40% Objective Response Rate and a 9 month Progression Free Survival average. Prescient Therapeutics believes as a new treatment option it can potentially gain FDA approval after a single Phase 2 study.


What are the Best ASX Stocks to invest in right now?

Check our ASX buy/sell tips